Skip to main content
. 2021 Jul 14;12:703481. doi: 10.3389/fpsyt.2021.703481

Table 2.

Changes in neuropsychiatric performance during COVID-19 pandemic confinement.

Overal AD
Baseline Follow-up p-value Baseline Follow-up p-value
Follow-up Interval, mean (SD) 14.07 ± 2.87 13.95 ± 2.61
Confinement Interval, mean (SD) 9.01 ± 1.82 8.89 ± 1.91
CDR, (n, %) 1.81 ± 0.89 1.83 ± 0.91 0.038 1.92 ± 0.82 1.91 ± 0.83 ns
0.5 20 (9.8) 27 (13.2) ns - 7 (5.3) ns
1 67 (32.7) 55 (26.8) ns 49 (37.4) 38 (29.0) ns
2 60 (29.3) 63 (30.7) ns 43 (32.8) 49 (37.4) ns
3 58 (28.3) 60 (29.3) ns 39 (29.8) 37 (28.2) ns
C-MMSE, mean (SD) 16.50 ± 8.16 14.96 ± 9.02 <0.001 15.64 ± 7.32 14.24 ± 8.15 <0.001
MOCA, mean (SD) 12.60 ± 7.54 11.47 ± 8.18 <0.001 11.76 ± 6.84 10.65 ± 7.41 <0.001
ADL, mean (SD) 30.97 ± 13.60 36.67 ± 18.61 <0.001 31.06 ± 13.31 37.40 ± 18.12 <0.001
NPI, (n, %) 8.15 ± 10.35 10.40 ± 12.70 0.001 7.27 ± 9.61 9.63 ± 12.37 0.028
Delusions 36 (17.6) 34 (16.6) ns 20 (15.3) 17 (13.0) ns
Hallucinations 39 (19.0) 47 (22.9) ns 21 (16.0) 29 (22.1) ns
Agitation 53 (25.9) 46 (22.4) ns 30 (22.9) 25 (19.1) ns
Depression 56 (27.3) 63 (30.7) ns 37 (28.2) 36 (27.5) ns
Anxiety 53 (25.9) 53 (25.9) ns 32 (24.4) 30 (22.9) ns
Euphoria 6 (2.9) 10 (4.9) ns 3 (2.3) 7 (5.3) ns
Apathy 73 (35.6) 72 (35.1) ns 48 (36.6) 40 (30.5) ns
Disinhibition 20 (9.8) 23 (11.2) ns 9 (6.9) 12 (9.2) ns
Irritability 70 (34.1) 73 (35.6) ns 38 (29.0) 42 (32.1) ns
Aberrant motor behavior 41 (20.0) 48 (23.4) ns 25 (19.1) 33 (25.2) ns
Sleep disturbances 57 (27.8) 76 (37.1) ns 27 (20.6) 43 (32.8) 0.035
Appetite disturbances 39 (19.0) 37 (18.0) ns 28 (21.4) 25 (19.1) ns

CI, cognitive impairment; AD, Alzheimer's disease; SD, standard deviation; CDR, Clinical Dementia Rate; C-MMSE, Chinese Mini-Mental State Examination; MoCA, the Montreal Cognitive Assessment; ADL, the activities of daily living; NPI, the Neuropsychiatric Inventory.